Impact of the COVID-19 Pandemic on Drug Use and Monitoring of Cancer Patients

Cancer Clinical Trial

— ONCORAL-Covid  

Official title:

Assessment of the Impact of the COVID-19 Pandemic on Drug Use and on the Perception of Remote Monitoring by Cancer Patients Followed in the ONCORAL Program

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05069662
• Other study ID #: 69HCL21_0163
• Status: Completed
• Start date: October 5, 2021
• Est. completion date: January 5, 2022

Study information

• Verified date: January 2022
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The COVID-19 pandemic has profoundly changed the organisation of care. Teleconsultation has replaced hospital medical consultations in order to reduce the risk of patient exposure to the virus. Within the framework of the Oncoral multidisciplinary outpatient / hospital program of follow-up, carried out by the Hospices Civils de Lyon for ambulatory patients treated with oral anticancer drugs, interviews with the pharmacist and/or nurse, which were previously organised face-to-face, have been replaced by telephone interviews, ensuring continuity of follow-up for patients without having to come to the hospital. This study focuses on a telephone survey to describe the impact of the COVID-19 pandemic health crisis on the drug exposure of cancer patients followed in the Oncoral program, their treatment management, their perception of teleconsultation and their IT resources for remote monitoring.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: January 5, 2022
• Est. primary completion date: January 5, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients aged 18 and over
• Ambulatory patients treated with oral anticancer drugs and benefiting from the ONCORAL multidisciplinary outpatient / hospital program
• Having benefited from a remote monitoring between March 16, 2020 and May 11, 2020 (the COVID-19 pandemic-related containment period)
• Patients who do not object to participating in the survey and to the use of the data collected

Exclusion Criteria:

• Patients who do not speak French
• Patients living in an institution
• Patients protected by law
• Patients included in a drug clinical trial
• Patients refusing to participate in the survey and / or not responding to the 2 telephone calls requesting their participation and / or not responding to any of these calls
• Patients choosing to stop the interview and no longer answering to the questions asked

Related Conditions & MeSH terms

• Cancer
• COVID-19

Intervention

Other:
• Directive Interview
One directive interview conducted by telephone

Locations

Country	Name	City	State
France	Service Pharmaceutique, Hospices Civils de Lyon	Pierre-Bénite

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients reporting a change in drug use during the COVID-19 pandemic-related containment period.	Percentage of patients reporting a change in medication use and / or a change medication management and / or a change in oral anticancer drug adherence during the COVID-19 pandemic-related containment period.	Inclusion